AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2110954 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.35 mg/kg
Number of subjects: 80
Study 2110954 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.45 mg/kg
Number of subjects: 80
Study 2110954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 394555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric 5% lidocaine with 75 mg/ml glucose concentration
Number of subjects: 0
Study 394555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric 5% lidocaine with 50 mg/ml glucose concentration
Number of subjects: 0
Study 394555 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both hyperbaric 5% lidocaine solutions
Number of subjects: 0
Study 11841067 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible membrane (BCM, polysulfone)
Number of subjects: 41
Study 30421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of imatinib therapy
Number of subjects: 99
Study 30421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib treatment after molecular recurrence
Number of subjects: 99
Study 30421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from diagnosis to discontinuation of imatinib therapy
Number of subjects: 99
Study 30421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of imatinib therapy
Number of subjects: 99
Study 29499839 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Traveller intervention (10-min physically active Virtual Field Trips three times a week for six weeks)
Number of subjects: 5
Study 29499839 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Traveller intervention
Number of subjects: 5
Study 27212183 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 70
Study 27212183 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 70
Study 24610183 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum AVS content
Number of subjects: 272
Study 24610183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate AVS content
Number of subjects: 272
Study 24610183 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum AVS content
Number of subjects: 272
Study 24610183 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard AVS content
Number of subjects: 272
Study 24610183 — intervention group
Group type: COMPARATOR
Intervention: All groups (minimum, intermediate, maximum, standard)
Number of subjects: 272
Study 22282101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol
Number of subjects: 73
Study 22282101 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg estradiol
Number of subjects: 73
Study 22282101 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375 mg estradiol
Number of subjects: 73
Study 22282101 — intervention group
Group type: COMPARATOR
Intervention: 0.27 mg estradiol
Number of subjects: 73
Study 22282101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21050549 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (0.2g/kg intravenously before conception, continued every 4 weeks until the 20th gestational week)
Number of subjects: 60
Study 21050549 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 60
Study 21050549 — intervention group
Group type: COMPARATOR
Intervention: Control (Traditional Chinese medicine or/and progesterone)
Number of subjects: 60
Study 21050549 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 17698724 — intervention group
Group type: EXPERIMENTAL
Intervention: EST (established recommendations)
Number of subjects: 796
Study 17698724 — intervention group
Group type: EXPERIMENTAL
Intervention: EST+DASH (established recommendations plus DASH dietary pattern)
Number of subjects: 796
Study 17698724 — intervention group
Group type: COMPARATOR
Intervention: Advice only control group
Number of subjects: 796
Study 17698724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EST and EST+DASH
Number of subjects: 796
Study 17698724 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure, lipids, and homeostasis model assessment
Number of subjects: 796
Study 15703502 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 0
Study 15703502 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0
Study 15703502 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 0
Study 15703502 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10-20 mg
Number of subjects: 0
Study 15703502 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20-40 mg
Number of subjects: 0
Study 15703502 — intervention group
Group type: COMPARATOR
Intervention: Branded simvastatin 10-80 mg
Number of subjects: 0
Study 15703502 — intervention group
Group type: COMPARATOR
Intervention: Generic simvastatin 40-80 mg
Number of subjects: 0
Study 12213159 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (5 microg) intravitreal injection
Number of subjects: 30
Study 12213159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no daunorubicin)
Number of subjects: 30
Study 10458045 — intervention group
Group type: EXPERIMENTAL
Intervention: Social phobia patients
Number of subjects: 0
Study 10458045 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder patients
Number of subjects: 0
Study 10458045 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 7608243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg intravenously every six hours for four doses)
Number of subjects: 59
Study 7608243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution, intravenously every six hours for four doses)
Number of subjects: 59
Study 1695308 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (mean dose of 3.6 mg daily)
Number of subjects: 159
Study 1695308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (mean dose of 50 mg daily)
Number of subjects: 159
Study 1695308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 656265 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary oxprenolol
Number of subjects: 2
Study 656265 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary metoprolol
Number of subjects: 2
Study 656265 — intervention group
Group type: COMPARATOR
Intervention: Plasma oxprenolol
Number of subjects: 2
Study 656265 — intervention group
Group type: COMPARATOR
Intervention: Plasma metoprolol
Number of subjects: 2
Study 30971174 — intervention group
Group type: EXPERIMENTAL
Intervention: N-SORB (1 mL, twice daily)
Number of subjects: 46
Study 30971174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 27230030 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Conditioning (PostCond)
Number of subjects: 78
Study 27230030 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 25347938 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ipragliflozin once daily for 24 weeks
Number of subjects: 0
Study 25347938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25347938 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ipragliflozin
Number of subjects: 0
Study 23873790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based art therapy (MBAT)
Number of subjects: 191
Study 23873790 — intervention group
Group type: COMPARATOR
Intervention: Standard educational support
Number of subjects: 191
Study 22142348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCTZ 150/12.5 mg
Number of subjects: 860
Study 22142348 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 860
Study 19197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liarozole (75 or 150 mg/day)
Number of subjects: 11
Study 19197536 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no treatment)
Number of subjects: 11
Study 16492838 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine sulfate 100 mg
Number of subjects: 26
Study 16492838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 14601047 — intervention group
Group type: EXPERIMENTAL
Intervention: Proline
Number of subjects: 0
Study 14601047 — intervention group
Group type: EXPERIMENTAL
Intervention: Proline with ASC
Number of subjects: 0
Study 14601047 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 10789532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dynamic psychotherapy (IDP)
Number of subjects: 0
Study 10789532 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial therapists
Number of subjects: 0
Study 8673810 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDAS Lyme Screen II (LYT II)‐bioMérieux
Number of subjects: 112
Study 8673810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyme Borreliosis‐Dako
Number of subjects: 112
Study 8673810 — intervention group
Group type: EXPERIMENTAL
Intervention: Borrelia Recombinant‐Biomedica
Number of subjects: 112
Study 8673810 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 112
Study 8673810 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroborreliosis patients
Number of subjects: 112
Study 8673810 — intervention group
Group type: EXPERIMENTAL
Intervention: bioMérieux test
Number of subjects: 112
Study 8673810 — intervention group
Group type: EXPERIMENTAL
Intervention: Dako‐IgG
Number of subjects: 112
Study 8673810 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedica‐IgG
Number of subjects: 112
Study 1365489 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxicam (20mg/day)
Number of subjects: 40
Study 1365489 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75mg/day)
Number of subjects: 40
Study 1365489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study 6614773 — intervention group
Group type: EXPERIMENTAL
Intervention: High negative pressure drain
Number of subjects: 120
Study 6614773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low negative pressure drain
Number of subjects: 120
Study 6614773 — intervention group
Group type: COMPARATOR
Intervention: Simple tube drain
Number of subjects: 120
Study 31776742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential fluoroscopy guidance
Number of subjects: 385
Study 31776742 — intervention group
Group type: COMPARATOR
Intervention: Spiral guidance
Number of subjects: 385
Study 30679232 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282
Number of subjects: 2
Study 30679232 — intervention group
Group type: COMPARATOR
Intervention: HMG-CoA reductase inhibitor or blocking antibody against proprotein convertase subtilisin/kexin type 9
Number of subjects: 2
Study 28199463 — intervention group
Group type: EXPERIMENTAL
Intervention: AFL‐PDT (1 session)
Number of subjects: 45
Study 28199463 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT (2 sessions)
Number of subjects: 45
Study 24978160 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (135 randomized)
Number of subjects: 266
Study 24978160 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 266
Study 23713297 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needling therapy combined with rehabilitation training
Number of subjects: 88
Study 23713297 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture combined with rehabilitation training
Number of subjects: 88
Study 21402326 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest wall compression with vibrations and increased pressure support ventilation by 10 cm H(2)O
Number of subjects: 66
Study 21402326 — intervention group
Group type: COMPARATOR
Intervention: Manual chest wall compression with vibrations (no adjustment of ventilator settings)
Number of subjects: 66
Study 20126902 — intervention group
Group type: EXPERIMENTAL
Intervention: TR+ (non-surgical periodontal treatment)
Number of subjects: 75
Study 20126902 — intervention group
Group type: COMPARATOR
Intervention: TR- (no treatment for periodontal disease)
Number of subjects: 75
Study 20126902 — intervention group
Group type: COMPARATOR
Intervention: Total prosthesis (TP)
Number of subjects: 75
Study 17003306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO group; 45 mg/day)
Number of subjects: 20
Study 17003306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plc group)
Number of subjects: 20
Study 15515037 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microT magnetic field exposure
Number of subjects: 32
Study 15515037 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microT magnetic field exposure
Number of subjects: 32
Study 15515037 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 32
Study 15515037 — intervention group
Group type: COMPARATOR
Intervention: Condition out of the helmet (control)
Number of subjects: 32
Study 11115695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 201
Study 11115695 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix
Number of subjects: 201
Study 11115695 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix-Vaqta
Number of subjects: 201
Study 11115695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta-Havrix
Number of subjects: 201
Study 11115695 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 201
Study 9929284 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized reminder system
Number of subjects: 2013
Study 9929284 — intervention group
Group type: COMPARATOR
Intervention: Historic controls
Number of subjects: 2013
Study 7770136 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinizing therapy (group I)
Number of subjects: 65
Study 7770136 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (group II)
Number of subjects: 65
Study 7770136 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (group III)
Number of subjects: 65
Study 3291623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nix (permethrin 1% creme rinse)
Number of subjects: 435
Study 3291623 — intervention group
Group type: COMPARATOR
Intervention: Rid
Number of subjects: 435
Study 31585725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT (25 µg)
Number of subjects: 285
Study 31585725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 285
Study 30880698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with lopinavir/ritonavir plus lamivudine (DT group)
Number of subjects: 198
Study 30880698 — intervention group
Group type: COMPARATOR
Intervention: Chinese first-line triple-therapy regimen (TT group)
Number of subjects: 198
Study 28882910 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced lipid-based nutrient supplement (LNS)
Number of subjects: 100
Study 26882609 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group A
Number of subjects: 120
Study 26882609 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group B
Number of subjects: 120
Study 26882609 — intervention group
Group type: COMPARATOR
Intervention: Common treatment group
Number of subjects: 120
Study 24127770 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular catheter
Number of subjects: 2128
Study 24127770 — intervention group
Group type: COMPARATOR
Intervention: Femoral catheter
Number of subjects: 2128
Study 21438796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/day
Number of subjects: 345
Study 19032135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin otic solution 0.2% (twice daily for 7 days)
Number of subjects: 630
Study 19032135 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (3 times daily for 7 days)
Number of subjects: 630
Study 19032135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin otic solution 0.2% (for patients with P. aeruginosa)
Number of subjects: 630
Study 19032135 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with P. aeruginosa)
Number of subjects: 630
Study 19032135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin otic solution 0.2% (for patients with S. aureus)
Number of subjects: 630
Study 19032135 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with S. aureus)
Number of subjects: 630
Study 16802269 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympus HX‐200L‐135
Number of subjects: 80
Study 16802269 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson‐Cook Tri‐Clip
Number of subjects: 80
Study 11958590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical concentrations of interleukin‐10 (IL‐10)
Number of subjects: 70
Study 11958590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical concentrations of interleukin‐12 (IL‐12)
Number of subjects: 70
Study 11958590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of IL‐12 to IL‐10
Number of subjects: 70
Study 11958590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical concentrations of IL‐10 among nonsmokers
Number of subjects: 70
Study 11958590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical concentrations of IL‐10 during day 18‐27 of menstrual cycle
Number of subjects: 70
Study 10191325 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective color constancy task
Number of subjects: 27
Study 10191325 — intervention group
Group type: EXPERIMENTAL
Intervention: Color discrimination or higher-level visual tasks
Number of subjects: 27
Study 8672320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cardiac output measurement using the reverse Fick principle (cVO2)
Number of subjects: 9
Study 8672320 — intervention group
Group type: COMPARATOR
Intervention: Gas exchange method (mVO2)
Number of subjects: 9
Study 2179638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus cytosine arabinoside
Number of subjects: 200
Study 2179638 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin-based regimen
Number of subjects: 200
Study 383274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-phenylalanine mustard (L-PAM)
Number of subjects: 0
Study 6861862 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus codeine 60 mg
Number of subjects: 90
Study 6861862 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 90
Study 6861862 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 90
Study 6861862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30536047 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of analgesia and femoral nerve block
Number of subjects: 40
Study 30536047 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block alone
Number of subjects: 40
Study 29522223 — intervention group
Group type: EXPERIMENTAL
Intervention: toriCAM application
Number of subjects: 22
Study 29522223 — intervention group
Group type: COMPARATOR
Intervention: freehand marking method
Number of subjects: 22
Study 29522223 — intervention group
Group type: COMPARATOR
Intervention: slit-lamp marking method
Number of subjects: 22
Study 27068628 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Dietary Inflammatory Index (DII) scores (Quartile 4)
Number of subjects: 7743
Study 27068628 — intervention group
Group type: COMPARATOR
Intervention: Lower Dietary Inflammatory Index (DII) scores (Quartile 1)
Number of subjects: 7743
Study 24612093 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 10 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Number of subjects: 220
Study 24612093 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 12 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Number of subjects: 220
Study 24612093 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 14 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Number of subjects: 220
Study 22506674 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Coordination Training (PCT)
Number of subjects: 294
Study 22506674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Training (CBTr)
Number of subjects: 294
Study 22506674 — intervention group
Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 294
Study 19606244 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N hydrochloric acid (HCl) infusion
Number of subjects: 29
Study 19606244 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 29
Study 17621237 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir (TMC114) with low-dose ritonavir (600/100 mg twice daily)
Number of subjects: 327
Study 15590214 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogen combined with 5 mg medroxyprogesterone acetate
Number of subjects: 124
Study 15590214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 124
Study 15590214 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg transdermal estrogen alone
Number of subjects: 124
Study 15590214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 12381833 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for the index finger abductors (n=8)
Number of subjects: 16
Study 12381833 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 16
Study 10022995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (70 mg/m2) and intravenous carboplatin (target AUCs of 4, 5, 6, and 7) with G-CSF (50 microgram/m2 from day 7 to 16)
Number of subjects: 25
Study 10159752 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.010" balloon PTCA system
Number of subjects: 50
Study 10159752 — intervention group
Group type: COMPARATOR
Intervention: 0.014" balloon PTCA system
Number of subjects: 50
Study 10159752 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced fellow as primary operator
Number of subjects: 50